Abstract Epidemiologic observations and preclinical experimental investigations suggest that the prevention or reversal of precancers should be an effective strategy in humans to control cancer. Although "proof of principle" has been established in humans, the results of randomized trials have not been confirmatory in most cases. Toxicity in normal or near-normal populations has also been greater than anticipated. We examine the problems associated with testing chemoprevention agents in humans and offer a process and guidelines that may better inform the logical development of this relatively young clinical field.
Introduction
The word "chemoprevention," with reference to cancer, was coined in 1976 and has evolved to encompass the suppression or reversal of cancer using natural or synthetic compounds (Sporn et al. 1976; Meyskens 1992a,b) . Both prior to 1976 and subsequently, a considerable amount of epidemiologic and preclinical experimental evidence has accumulated suggesting that human cancer should either be preventable or else reversible or suppressible in its early stages. However, definitive large randomized trials in humans based on epidemiologic observations have generally yielded disappointing results (review cervix, Follen et al. 2001; colorectal, Viner et al. 2002) , with adverse results (more lung cancers) produced by b-carotene supplementation in smokers (Omenn et al. 1996 ) and no effect of fiber supplementation on adenomatous polyp recurrence in patients with one or more prior adenoma (Alberts et al. 2000; Schatzkin et al. 2000) . Randomized trials based on experimental data have yielded somewhat more encouraging results, with retinoids being demonstrated to clearly suppress the development of second cancers in head and neck cancer patients (Hong et al. 1990) , and tamoxifen given at standard doses being effective in substantially decreasing the incidence of breast cancers in women at high risk for this event (Fisher et al. 1998) . However, both studies demonstrated a sufficiently high level of toxicity (for putatively healthy individuals) such that neither compound has entered widespread usage, despite FDA approval for the latter indication. Attempts to use a lower non-toxic dose of retinoid were unsuccessful and ineffective in preventing secondary lung cancers in a well-defined cohort (Lippman et al. 2001) . Similarly, the attempt to prevent prostate cancer with finasteride, a specific inhibitor of the conversion of testosterone to its active form dihydrotestosterone, has produced mixed results. The total incidence of prostate cancer was significantly decreased in a large randomized placebo-controlled trial; however, the number of advanced (!Gleason 7) tumors was significantly increased and a slightly increased incidence of urogenital side effects was noted (Thompson et al. 2003 ). Whether or not finasteride is approved by the FDA, these findings suggest that this agent may not be widely adopted.
One of us (F.M.) has posed a number of questions in this series of conferences (Meyskens 1998; Meyskens 2000a,b,c) . The two broad questions we must now ask ourselves are: (1) Why have we been so unsuccessful in translating positive epidemiologic and experimental findings to clinical benefit? (2) How should we move the field of chemopreventive agent development forward in a manner that is more productive?
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Through the Retrospectroscope
Based on the results of randomized studies done to date, a series of questions that need to be addressed, discussed, and debated has emerged:
1. Are the results of epidemiologic observations alone ever enough to embark on a phase III trial?
Studies of non-oncological diseases have suggested that a very substantial effect must be evident in epidemiologic observations if a significant result is to be demonstrated in a randomized clinical trial (Ioannidis et al. 2001 ).
In general, the effect demonstrated in a randomized trial is 40%-50% less than would be anticipated from observation studies. This caveat therefore
